CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT) Meeting Abstract
| Authors: | Gerritsen, W. R.; Kwon, E. D.; Fizazi, K.; Bossi, A.; Van den Eertwegh, A.; Logothetis, C.; Scher, H. I.; Beer, T. M.; McHenry, M. B.; Gagnier, P.; Drake, C. G. |
| Abstract Title: | CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT) |
| Meeting Title: | 17th European Cancer Conference (ECCO 17) |
| Journal Title: | European Journal of Cancer |
| Volume: | 49 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2013 Sep 27-Oct 1 |
| Meeting Location: | Amsterdam, Netherlands |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-09-01 |
| Start Page: | S678 |
| End Page: | S679 |
| Language: | English |
| ACCESSION: | WOS:000326843604212 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(13)70064-9 |
| Notes: | Meeting Abstract: 2850 -- 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity -- SEP 27-OCT 01, 2013 -- Amsterdam, NETHERLANDS -- Source: Wos |
